# A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

> **NCT07001475** · PHASE1 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 96 (estimated)

## Conditions studied

- Borderline Personality Disorder
- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** BI 3031185
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07001475
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-12
- **Primary completion:** 2026-10-27
- **Final completion:** 2026-11-27
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07001475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07001475, "A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07001475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*